


- ☒ No additional fee is required. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §1.16 and §1.17, which may be required, or credit any overpayment, to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-6385
Date: July 19, 2006


Terence J. Bogie
Attorney for Applicants
Reg. No. 44,544



CASE HA726 DIV-1

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper(s) referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Julie Staszewski
Type or print name

[Signature]
Signature

July 19, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ATWAL ET AL.

Examiner: Rao, D.

APPLICATION NO: 10/660,878

Art Unit: 1624

FILED: SEPTEMBER 12, 2003

FOR: HETEROCYCLIC DIHYDROPYRIMIDINE COMPOUNDS

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT & RESPONSE TO FINAL REJECTION

Sir:

Applicants are appreciative of the time afforded them by the Examiner in helping identify subject matter within the pending claims of the above-identified patent application that meets statutory requirements for allowance. This response is directed at that subject matter, and is provided in response to the Final Office Action that was issued in the above-identified application on May 19, 2006 and a telephone conversation that applicants' attorney had with the Examiner on July 18, 2006.

Amendments to the Claims are reflected in the amendments in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 47 of this paper.